• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by InspireMD Inc.

    11/18/25 4:15:40 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care
    Get the next $NSPR alert in real time by email
    S-8 1 forms-8.htm S-8

     

    As filed with the Securities and Exchange Commission on November 18, 2025

     

    Registration No. 333-

     

     

     

    United States

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    INSPIREMD, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   26-2123838

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    6303 Waterford District Drive

    Suite 215

    Miami, Florida 33126

    (Address of Principal Executive Offices)

     

    InspireMD, Inc. 2021 Equity Compensation Plan

    (Full title of the plan)

     

    Marvin Slosman

    President and Chief Executive Officer

    InspireMD, Inc.

    6303 Waterford District Drive

    Suite 215

    Miami, Florida 33126

    (888) 776-6804

    (Name, Address and Telephone Number of Agent For Service)

     

    Copies to:

    Raffael M. Fiumara, Esq.

    Gary Emmanuel, Esq.

    Sami B. Ghneim, Esq.

    Greenberg Traurig, P.A.

    333 S.E. 2nd Avenue, Suite 4400

    Miami, Florida 33131

    Tel: (305) 579-0500

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act

     

    Large accelerated filer ☐   Accelerated filer ☐   Non-accelerated filer ☒   Smaller reporting company ☒   Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    InspireMD, Inc. 2021 Equity Compensation Plan

     

    The purpose of this Registration Statement on Form S-8 (this “Registration Statement”) is for InspireMD, Inc. (the “Company”) to register an additional 4,723,370 shares of common Stock, par value $0.0001 per share, for issuance under the Company’s 2021 Equity Compensation Plan (the “Plan”). In accordance with General Instruction E of Form S-8, the contents of the Company’s Registration Statements on Form S-8 (File Nos. 333-260216 and 333-272003), filed with the Securities and Exchange Commission (the “Commission”) on October 13, 2021 and May 17, 2023, respectively, are incorporated herein by reference and the information required by Part II is omitted, except as supplemented by the information set forth below.

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Item 1. Plan Information.*

     

    Item 2. Registrant Information and Employee Plan Annual Information. *

     

    * The documents containing the information specified in this Part I of Form S-8 (plan information and Registrant information and employee plan annual information) will be sent or given to employees as specified by the Commission pursuant to Rule 428(b)(1) of the Securities Act. Such documents are not required to be and are not filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II hereof, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents, which have been filed by the Company with the Commission are incorporated by reference in and made a part of this registration statement, as of their respective dates:

     

      (a) the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 12, 2025;
         
      (b) the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, June 30, 2025 and September 30, 2025, filed with the Commission on May 8, 2025, August 4, 2025 and November 10, 2025, respectively;
         
      (c) the Company’s Definitive Proxy Statement on Schedule 14A filed on April 15, 2025, to the extent specifically incorporated by reference into Part III of the Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 12, 2025;
         
      (c) the Current Reports on Form 8-K (other than the information furnished pursuant to Item 2.02 or 7.01 thereof or related exhibits furnished pursuant to Item 9.01 thereof) filed with the SEC on March 12, 2025, May 9, 2025, June 3, 2025, June 3, 2025, June 13, 2025, June 24, 2025, July 9, 2025, July 31, 2025, August 5, 2025, September 8, 2025, September 17, 2025 and November 4, 2025; and
         
      (d) the description of the Company’s Common Stock in Exhibit 4.1 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 12, 2025, and as may be further updated or amended in any amendment or report filed for such purpose.

     

    All documents subsequently filed by us with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of filing of such documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement herein, or in any subsequently filed document which also is or is deemed to be incorporated by reference, modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

     

    Item 8. Exhibits.

     

    A list of exhibits filed with this Registration Statement on Form S-8 is set forth on the Exhibit Index and is incorporated herein by reference.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Miami, Florida, United States, on the 18th day of November, 2025.

     

      INSPIREMD, INC.
         
      By: /s/ Marvin Slosman
      Name: Marvin Slosman
      Title: Chief Executive Officer

     

    power of attorney and signatures

     

    We, the undersigned officers and directors of InspireMD, Inc., hereby severally constitute and appoint Marvin Slosman and Michael Lawless, and each of them individually, our true and lawful attorney to sign for us and in our names in the capacities indicated below any and all amendments or supplements, including any post-effective amendments, to this registration statement on Form S-8 and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming our signatures to said amendments to this registration statement signed by our said attorney and all else that said attorney may lawfully do and cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this registration statement on Form S-8 has been signed below by the following persons in the capacities and on the dates indicated.

     

    Person   Capacity   Date
             
    /s/ Marvin Slosman   Chief Executive Officer   November 18, 2025
    Marvin Slosman   (Principal Executive Officer), President, Director    
             
    /s/ Michael Lawless   Chief Financial Officer,   November 18, 2025
    Michael Lawless   Principal Financial and Accounting Officer)    
             
    /s/ Paul Stuka   Chairman of the Board of Directors   November 18, 2025
    Paul Stuka        
             
    /s/ Kathryn Arnold   Director   November 18, 2025
    Kathryn Arnold        
             
    /s/ Michael Berman   Director   November 18, 2025
    Michael Berman        
             
    /s/ Raymond Cohen   Director   November 18, 2025
    Raymond Cohen        
             
    /s/ Dan Dearen   Director   November 18, 2025
    Dan Dearen        
             
    /s/ Gary Roubin, M.D.   Director   November 18, 2025
    Gary Roubin, M.D.        
             
    /s/ Scott R. Ward   Director   November 18, 2025
    Scott R. Ward        

     

     

     

     


    EXHIBIT INDEX

     

    Exhibit No.   Description
         
    3.1   Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2015)
    3.2   Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to Current Report on Form 8-K filed with the Securities and Exchange Commission on June 29, 2021)
    3.3   Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on May 25, 2016)
    3.4   Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on September 29, 2016)
    3.5   Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on March 15, 2017)
    3.6   Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitation of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on November 29, 2017)
    3.7   Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitation of Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on December 12, 2017)
    3.8   Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on February 7, 2018)
    3.11   Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc., dated March 27, 2019 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on March 28, 2019)
    3.12   Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc., dated April 14, 2021 (incorporated by reference to Exhibit 3.17 to Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2021)
    3.13   Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc., dated September 13, 2023 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on September 13, 2023)
    4.1   Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to Amendment No. 3 to Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 5, 2013)
    5.1*   Opinion of Greenberg Traurig, P.A.
    23.1*   Consent of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, independent registered public accounting firm for the registrant
    23.2*   Consent of Greenberg Traurig, P.A. (included in Exhibit 5.1)
    24.1*   Power of Attorney (included in the signature page)
    99.1   The Company’s 2021 Equity Compensation Plan (incorporated by reference to Annex A to the Company’s Proxy Statement on Schedule 14A filed with the Commission on August 12, 2021).
    107*   Filing Fee Table
         
    *   Filed herewith.

     

     

     

    Get the next $NSPR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NSPR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NSPR
    SEC Filings

    View All

    SEC Form S-8 filed by InspireMD Inc.

    S-8 - InspireMD, Inc. (0001433607) (Filer)

    11/18/25 4:15:40 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by InspireMD Inc.

    SCHEDULE 13G/A - InspireMD, Inc. (0001433607) (Subject)

    11/14/25 6:12:00 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by InspireMD Inc.

    SCHEDULE 13G/A - InspireMD, Inc. (0001433607) (Subject)

    11/14/25 4:22:26 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference

    MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to participate in a fireside discussion at the upcoming Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3rd at 12:30 pm Eastern Time (ET). A live audio webcast and replay of the discussion may be accessed on the "Investor Calendar" section of the company's website at: https://event.webcasts.com/starthere.jsp?ei=1744172&tp_key=a1a6262ba9 About InspireMD, Inc.InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by p

    11/19/25 4:41:45 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Reports Third Quarter 2025 Financial Results

    MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the third quarter and nine months ended September 30, 2025. Recent Business Highlights: Initiated U.S. commercial launch of the CGuard Prime carotid stent systemCompleted over 100 U.S. carotid procedures across leading hospitalsStrengthened leadership team with the appointment of Peter A. Soukas, M.D., as Chief Medical OfficerAppointed Dan Dearen to the Board of Directors as Audit Committee Chairman bringing valuable experience to InspireMD Marvin Slosma

    11/4/25 7:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Names Peter A. Soukas, M.D., as Chief Medical Officer

    MIAMI, Nov. 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Peter A. Soukas, M.D., as Chief Medical Officer to advance its mission to deliver best-in-class tools for carotid intervention. "We are thrilled to have Dr. Soukas join InspireMD to help lead our clinical and medical organization with strategy and oversight at this pivotal time for the Company," said Marvin Slosman, Chief Executive Officer of InspireMD. "His expertise and clinical practice focus in carotid intervention and peripheral vascular disease offer valuable insight

    11/3/25 7:30:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stuka Paul bought $21,758 worth of shares (13,431 units at $1.62), increasing direct ownership by 4% to 373,715 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    11/13/25 4:05:01 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Director Kester Thomas J bought $74,998 worth of shares (30,991 units at $2.42), increasing direct ownership by 8% to 420,758 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    8/1/25 5:00:23 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    CEO and President Slosman Marvin bought $24,999 worth of shares (10,330 units at $2.42), increasing direct ownership by 0.43% to 2,420,866 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    8/1/25 5:00:21 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stuka Paul bought $21,758 worth of shares (13,431 units at $1.62), increasing direct ownership by 4% to 373,715 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    11/13/25 4:05:01 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Director Roubin Gary S was granted 48,000 shares, increasing direct ownership by 8% to 656,425 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    10/9/25 4:05:23 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    New insider Dearen Danny L. claimed ownership of 58,017 shares (SEC Form 3)

    3 - InspireMD, Inc. (0001433607) (Issuer)

    9/24/25 4:00:13 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Leadership Updates

    Live Leadership Updates

    View All

    InspireMD Names Peter A. Soukas, M.D., as Chief Medical Officer

    MIAMI, Nov. 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Peter A. Soukas, M.D., as Chief Medical Officer to advance its mission to deliver best-in-class tools for carotid intervention. "We are thrilled to have Dr. Soukas join InspireMD to help lead our clinical and medical organization with strategy and oversight at this pivotal time for the Company," said Marvin Slosman, Chief Executive Officer of InspireMD. "His expertise and clinical practice focus in carotid intervention and peripheral vascular disease offer valuable insight

    11/3/25 7:30:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

    MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value through execution. "We are pleased to welcome Dan to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "He brings extensive experience, financial expertise, and

    9/17/25 8:00:00 AM ET
    $BBNX
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

    MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions. "We are thrilled to welcome Ray to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "We expect to benefit greatly from his vast insights and experience. His

    7/31/25 8:31:00 AM ET
    $KMTS
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Financials

    Live finance-specific insights

    View All

    InspireMD Reports Third Quarter 2025 Financial Results

    MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the third quarter and nine months ended September 30, 2025. Recent Business Highlights: Initiated U.S. commercial launch of the CGuard Prime carotid stent systemCompleted over 100 U.S. carotid procedures across leading hospitalsStrengthened leadership team with the appointment of Peter A. Soukas, M.D., as Chief Medical OfficerAppointed Dan Dearen to the Board of Directors as Audit Committee Chairman bringing valuable experience to InspireMD Marvin Slosma

    11/4/25 7:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD to Announce Third Quarter 2025 Financial Results

    MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD's website or by registering below. A replay of the webin

    10/21/25 4:05:00 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Reports Second Quarter 2025 Financial Results

    --- Management to host investor conference call today, August 5th, at 8:30am ET --- MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the second quarter and six months ended June 30, 2025. Recent Business Highlights: Received premarket application (PMA) approval from the U.S. Food and Drug Administration (FDA) for the CGuard Prime carotid stent systemCommenced commercial launch of the CGuard Prime carotid stent system in the U.S. MarketRaised $58 million in gross proceeds from an equity private placement and the exercise of existin

    8/5/25 8:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by InspireMD Inc.

    SC 13G - InspireMD, Inc. (0001433607) (Subject)

    12/4/24 4:31:06 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

    SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

    11/14/24 6:35:20 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

    SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

    10/28/24 4:02:11 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care